US61023L2079
US61023L2079
Monopar Therapeutics Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | -- | -- | -- |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 16.704.415 | 16.161.721 | 3.4% | |
| Operating Income | -16.704.415 | -16.161.721 | 3.4% |
| Pretax Income | -13.716.894 | -15.586.419 | 12.0% |
| Net Income Common Stockholders | -13.716.894 | -15.586.419 | 12.0% |
| -- | -- | -- | |
| -- | -- | -- |